Glaukos Corporation (GKOS): Price and Financial Metrics
Today's Latest Price: $42.72 USD
Jun 4 6:40pm Add GKOS to Watchlist Sign Up GKOS Stock Summary GKOS's price/sales ratio is 7.93; that's higher than the P/S ratio of 84.78% of US stocks. With a year-over-year growth in debt of 498.96%, GLAUKOS Corp's debt growth rate surpasses 96.36% of about US stocks. In terms of twelve month growth in earnings before interest and taxes, GLAUKOS Corp is reporting a growth rate of 817.83%; that's higher than 98.34% of US stocks. If you're looking for stocks that are quantitatively similar to GLAUKOS Corp, a group of peers worth examining would be VRNS, VCEL, LPSN, ORGS, and REFR. GKOS's SEC filings can be seen here. And to visit GLAUKOS Corp's official web site, go to www.glaukos.com. GKOS Price/Volume Stats
1.89B Glaukos Corporation (GKOS) Company Bio
Glaukos Corporation develops and commercializes products and procedures designed for the treatment of glaucoma. The company was founded in 1998 and is based in Laguna Hills, California.
GKOS Latest News Stream
All News Types Acquisition Barron's Commentary Corp. News Cramer Downgrade Earnings Guidance Down Guidance Up Mgmt Change New Coverage (Bullish) New Coverage (Neutral) Product News PT Lowered PT Raised PT Set (Bullish) Rating Reiterated (Bullish) Rating Reiterated (Neutral) Upgrade
Event/Time News Detail Loading, please wait... Latest GKOS News From Around the Web
Below are the latest news stories about GLAUKOS Corp that investors may wish to consider to help them evaluate GKOS as an investment opportunity.
Q1 2020 Glaukos Corp Earnings Call
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the William Blair 40th Annual Growth Stock Conference on Wednesday, June 10, 2020, at 3:20 p.m. CDT.
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various "on demand" presentations at the American Society of Cataract and Refractive Surgery (ASCRS) Virtual Annual Meeting, which will be held online on May 16-17, 2020.
Image source: The Motley Fool. Glaukos (NYSE: GKOS)Q1 2020 Earnings CallMay 07, 2020, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorWelcome to Glaukos Corporation's first-quarter 2020 financial results conference call.
Glaukos (GKOS) witnessed a contraction in gross margin but year-over-year revenue surge in Q1.
Read More 'GKOS' Stories Here
GKOS Price Returns
N/A Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.8729 seconds.